CJC-1295 and AOD-9604 Stack: Complete Protocol for Women

What These Two Peptides Are and Why They Are Stacked

These are two different molecules aimed at two different steps of the same fat-metabolism pathway, and that is the core rationale for combining them.

CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors in the pituitary and tells your pituitary to release more growth hormone in its natural pulsatile pattern. A 2006 dose-escalation study in healthy adults found that a single injection of CJC-1295 with drug affinity complex (DAC) produced GH increases of 2 to 10 times baseline, with elevated GH and IGF-1 sustained for up to 6 days. That prolonged action is distinctive and clinically meaningful when thinking about compounding frequency.

AOD-9604, by contrast, is not a GHRH analogue. It is a stabilised synthetic version of amino acids 176-191 on the C-terminal end of the human GH molecule. That fragment is the region thought to govern fat breakdown. A preclinical study published in Molecular and Cellular Endocrinology showed AOD-9604 stimulated lipolysis and inhibited lipogenesis in animal adipose tissue without the glucose-raising effects seen with full-length GH. The appeal is selectivity: fat effects, theoretically without IGF-1 elevation or insulin resistance.

Stacking them means you are simultaneously telling the pituitary to release more GH (CJC-1295) while also directly activating peripheral fat-cell receptors (AOD-9604). Whether the combination produces additive benefit over either alone has not been tested in a controlled human trial.

Why Women Are Specifically Interested

Women lose roughly 75% of their growth hormone pulse amplitude by their mid-40s compared with young adulthood, a steeper proportional drop than in men of the same age. That decline accelerates around perimenopause and is compounded by falling estrogen, which normally amplifies GH secretion. The result is a metabolic shift toward central adiposity, reduced lean mass, and slower recovery from exercise that many perimenopausal women notice acutely. This biological context explains why GH-targeted peptide stacks have found an audience in women aged 40-55 even though the clinical trials that exist enrolled mostly men or mixed cohorts without sex-stratified reporting.

The Evidence Base: What Is Actually Known (and What Is Not)

The honest answer is that the human evidence for this specific stack is sparse. You deserve to know that before reading dosing recommendations.

What the Animal and Early Human Data Show

AOD-9604 completed Phase II and III trials for obesity in the early 2000s under the brand name Tregopil/AOD9604 by Metabolic Pharmaceuticals. A Phase IIb randomised trial published in the International Journal of Obesity enrolled 300 obese adults and found 1 mg oral AOD-9604 daily produced modest but statistically significant weight loss versus placebo over 12 weeks. The FDA did not approve it for obesity. Those trials used oral AOD-9604, not subcutaneous, and they did not report sex-stratified outcomes or enrol women separately by hormonal status.

CJC-1295 human data is similarly limited to short-duration pharmacokinetic and safety studies. The 2006 trial in the Journal of Clinical Endocrinology and Metabolism enrolled 65 healthy adults but did not stratify by sex or menstrual phase.

The Evidence Gap in Women

Women have been historically under-represented in GH-axis peptide research. No published RCT has tested CJC-1295 or AOD-9604 specifically in perimenopausal or postmenopausal women. What practitioners currently use is extrapolated from general adult pharmacokinetic data, GH physiology literature in women, and patient-reported outcomes shared in clinical practice. That extrapolation may be reasonable mechanistically, but it is extrapolation. Any clinician who tells you the dosing for this stack is "proven" in women is overstating the data.

Sex-Specific Physiology: How Your Hormonal Status Changes the Response

Estrogen, GH, and the Menstrual Cycle

Estrogen is a potent modulator of GH secretion. During the follicular phase of your cycle, rising estrogen enhances pituitary sensitivity to GHRH, meaning CJC-1295 may produce a more pronounced GH pulse around days 7-14 of a regular cycle. During the luteal phase, GH pulse amplitude is generally lower. This means your response to the same CJC-1295 dose may vary across the month, something that is not accounted for in any current protocol because no one has studied it.

Perimenopause

In perimenopause, estrogen fluctuates unpredictably rather than following a tidy cycle. GH pulsatility becomes irregular. Some women in early perimenopause may respond vigorously to CJC-1295; others with very low estrogen states may see a blunted response because pituitary GHRH sensitivity is partly estrogen-dependent. A study in the Journal of Clinical Endocrinology and Metabolism confirmed that GH secretory dynamics differ significantly between premenopausal and postmenopausal women independent of age.

Post-Menopause

After menopause, GH pulse frequency falls further and IGF-1 is typically lower than in premenopausal peers. CJC-1295 can restore some of that lost pulsatility, but the baseline IGF-1 trajectory means post-menopausal women need careful IGF-1 monitoring to avoid overshooting into a supraphysiologic range. Women on systemic hormone therapy (HT) have higher IGF-1 baselines than those not on HT, which is relevant for setting your monitoring threshold.

PCOS

If you have PCOS, GH pulsatility is already altered, and IGF-1 signalling plays a direct role in the androgen excess that characterises the condition. Research published in Fertility and Sterility documented elevated basal GH and abnormal GH pulse patterns in women with PCOS. Adding CJC-1295 in PCOS without close IGF-1 and androgen monitoring is a meaningful risk, not a theoretical one.

Complete Dosing Protocol

This protocol reflects current practitioner-reported practice and mechanistic reasoning. It is not based on a published RCT. Treat every number as a starting point, not a ceiling, and adjust based on labs and clinical response.

Starting Doses

| Peptide | Starting Dose | Common Range | Route | Timing | |---|---|---|---|---| | CJC-1295 (no DAC) | 100 mcg | 100-300 mcg | Subcutaneous | Before bed | | CJC-1295 (with DAC) | 1 mg | 1-2 mg | Subcutaneous | Once weekly | | AOD-9604 | 250 mcg | 250-500 mcg | Subcutaneous | Morning, fasted |

Most practitioners separate CJC-1295 and AOD-9604 by timing. CJC-1295 without DAC is given at night to align with the normal nocturnal GH surge. AOD-9604 is given in the morning in a fasted state because food-triggered insulin will suppress lipolysis and blunt its fat-mobilising effect.

Injection Technique for Women

Use a 29-gauge or 31-gauge insulin syringe. Rotate injection sites among the lower abdomen, outer thigh, and upper buttock. Women typically have a thinner subcutaneous layer than men in abdominal sites, particularly post-menopausal women with less subcutaneous fat. Inject slowly at 45 degrees if your pinched skin fold is thin. Refrigerate reconstituted peptide at 2-8 degrees Celsius and use within 21-28 days.

Cycle Length and Rest Periods

Most protocols run 12-16 weeks on, followed by a 4-8 week break. The rationale is avoiding pituitary desensitisation to sustained GHRH stimulation, though the evidence for this rest-period approach is mechanistic inference rather than direct human data. IGF-1 should be checked at baseline, at 6 weeks into the cycle, and at the end before deciding to restart.

Lab Monitoring

• IGF-1 (target: mid-normal for your age, not top of range)
• Fasting glucose and insulin (CJC-1295 can impair insulin sensitivity)
• HbA1c if you have any history of insulin resistance or PCOS
• Thyroid panel (GH affects T4-to-T3 conversion)
• Sex hormones (LH, FSH, estradiol, testosterone) at baseline

Women-specific monitoring framework at WomanRx: because estrogen status modulates both GH secretion and IGF-1 clearance, we recommend adding estradiol to every IGF-1 draw during this stack. A rising IGF-1 in the context of falling estradiol (as in perimenopause) represents a different clinical picture than the same IGF-1 value in a premenopausal woman. Reading IGF-1 without estradiol context is incomplete monitoring for women on GH-axis peptides.

Pregnancy, Lactation, and Contraception

Stop both peptides before attempting to conceive. This is not a nuanced recommendation. It is categorical.

Pregnancy

Neither CJC-1295 nor AOD-9604 has been assigned an FDA pregnancy category under the old classification system (both predate the current labelling rule), and neither has been evaluated in human pregnancy studies. Animal reproductive toxicity data are absent from the published literature for both compounds in their injectable compounded forms.

GH-axis stimulation during pregnancy carries theoretical risk. Endogenous GH is physiologically suppressed in early pregnancy and replaced by placental GH, which has a distinct receptor-binding profile. Exogenous GHRH stimulation via CJC-1295 during this replacement transition is not studied and could disrupt normal placental GH signalling. The ACOG general principle on unclassified compounded biologics in pregnancy is to avoid agents lacking adequate safety data.

AOD-9604 activates lipolysis. Maternal lipid mobilisation in excess of physiologic pregnancy demands may theoretically compromise placental lipid transfer. No human data exist.

If you are sexually active and using CJC-1295 or AOD-9604, use reliable contraception. Barrier methods alone are insufficient for a daily injection protocol. Combined oral contraceptive pills, IUDs, or other highly effective methods are recommended for the duration of any peptide cycle.

Lactation

No pharmacokinetic data on transfer of CJC-1295 or AOD-9604 into human breast milk exist. Given the absence of any safety data and the theoretical risk of GH-axis perturbation in a breastfeeding infant, both peptides should be considered incompatible with breastfeeding. The NIH LactMed database does not list either compound because no transfer data have been submitted. Absence from LactMed does not mean safety.

Fertility Considerations

If you are trying to conceive, the picture is more nuanced. GH has a documented role in folliculogenesis and endometrial receptivity. A meta-analysis in Fertility and Sterility found GH co-treatment in poor-ovarian-responder IVF cycles improved live birth rates versus no adjuvant GH. However, that data used pharmaceutical-grade GH under close monitoring in a supervised IVF context. Using unregulated compounded CJC-1295 while trying to conceive spontaneously is a different situation entirely and is not supported by evidence.

Who This Stack May Be Right For and Who Should Not Use It

Potentially Suitable Candidates

You may be a reasonable candidate for this stack, under medical supervision, if you:

• Are a non-pregnant, non-breastfeeding adult woman aged 35-60 with documented body-composition goals
• Have normal fasting glucose and no personal history of malignancy
• Have IGF-1 in the lower half of your age-adjusted reference range at baseline
• Are working with a physician or NP who will order and interpret labs
• Understand this is off-label use with no long-term human safety data

Women Who Should Not Use This Stack

This stack is not appropriate if you:

• Are pregnant, planning pregnancy within 6 months, or breastfeeding
• Have active cancer or a personal history of any hormone-sensitive cancer (breast, ovarian, endometrial), because GH-axis stimulation raises IGF-1, which has mitogenic properties and elevated IGF-1 has been associated with breast cancer risk in observational data
• Have uncontrolled type 2 diabetes or significant insulin resistance, because CJC-1295 can worsen glucose tolerance
• Have PCOS with elevated androgens or insulin resistance that is not yet managed
• Have active thyroid disease that is not treated
• Are under 25, as the GH axis is still physiologically active and stimulation may not confer benefit and could interfere with normal hormonal patterns

Perimenopause and Post-Menopause: A Nuanced Case

Perimenopausal and postmenopausal women have the strongest biological rationale for GH-axis support given the steep decline in GH pulsatility at this life stage. The concern is that this is also the life-stage group with the highest background breast cancer risk, making IGF-1 monitoring non-negotiable. A postmenopausal woman with a BRCA1/2 variant or a first-degree relative with breast cancer should not use this stack.

Potential Side Effects and Risks Specific to Women

Water Retention and Bloating

CJC-1295 raises GH, and GH promotes sodium and water retention. Women are more sensitive to GH-mediated fluid retention than men, particularly in the luteal phase when progesterone already contributes to bloating. Starting at the lowest dose and titrating slowly reduces this risk.

Glucose and Insulin Changes

GH is counter-regulatory to insulin. Women with underlying insulin resistance (common in PCOS and perimenopause) may see fasting glucose creep upward on CJC-1295. A study in the Journal of Clinical Endocrinology and Metabolism found transient elevations in fasting glucose in healthy adults receiving CJC-1295. Monitoring fasting glucose monthly is appropriate.

Injection Site Reactions

Subcutaneous nodules and transient redness are the most common local reactions. Women with lipodystrophy from prior injections (including insulin users or women with lipoatrophy) should rotate sites carefully.

Supply and Quality Risk

Both peptides are sold in the US as "research chemicals" from compounding pharmacies or online vendors. The FDA does not regulate their purity, concentration, or sterility for human use. The FDA has issued multiple warnings about compounded peptides lacking verified identity and potency. A 2023 analysis of compounded peptides found that a meaningful fraction of tested vials contained incorrect concentrations or contaminants. Choose only a 503A or 503B compounding pharmacy if you pursue this route, and ask for a certificate of analysis.

How This Stack Compares to Other Options at the Same Life Stage

| Option | Evidence Level | IGF-1 Effect | FDA Status | Women-Specific Data | |---|---|---|---|---| | CJC-1295 + AOD-9604 | Mechanistic / animal | Raises IGF-1 (CJC) | Not approved | Very limited | | CJC-1295 + Ipamorelin | Mechanistic / small human | Raises IGF-1 | Not approved | Very limited | | Pharmaceutical GH (somatropin) | RCT-level | Raises IGF-1 | FDA-approved (specific indications) | Some adult-women data | | Lifestyle + resistance training | Multiple RCTs | Physiologic range | N/A | Strong in perimenopausal women | | GLP-1 receptor agonists (semaglutide) | Multiple large RCTs | No direct effect | FDA-approved (obesity) | Sex-stratified data in STEP trials |

If your primary goal is weight loss and body composition, GLP-1 receptor agonists have a substantially stronger evidence base and FDA approval for obesity. The STEP 1 trial showed semaglutide 2.4 mg weekly produced a mean 14.9% body weight reduction over 68 weeks in adults with obesity or overweight with a weight-related comorbidity. That is a real comparison point when evaluating where to invest your time, money, and physiologic risk.

Practical Checklist Before Starting

Before you inject anything, work through this list with your provider:

1. Get baseline labs: IGF-1, fasting glucose, HbA1c, estradiol, LH/FSH (if relevant to your life stage), thyroid panel, full metabolic panel.
2. Confirm you are not pregnant. A urine pregnancy test on the day of your first injection is reasonable.
3. Confirm your contraception method is highly effective if you are of reproductive age.
4. Source from a licensed 503A or 503B compounding pharmacy. Request a certificate of analysis.
5. Start at the lowest dose listed. Do not begin both peptides simultaneously. Start CJC-1295 alone for 2 weeks, then add AOD-9604 so you can identify which peptide causes any side effect.
6. Set a 6-week IGF-1 recheck before the end of your first cycle.
7. Document your symptoms, weight, and sleep quality weekly so you have objective data to bring to your provider.